|
As of April
2016 the REVISE-Diabesity
Study HAS COMPLETED ONE YEAR and
has one more year to run.
This study is a multi-centre
randomised controlled trial evaluating the effectiveness of
a new device called Endobarrier combined with a GLP-1
receptor analogue
(liraglutide) or used alone.
REVISE-Diabesity is funded
by ABCD is supported by the NHS, as one of the National
Institute for Health Research’ (NIHR) Clinical (Diabetes)
Research Network Portfolio Studies. The presentation of the
one year results triggered a
BBC news item which is available to view. A presentation
of the 1-year results, including assessment of 10-year
cardiovascular risk, can be viewed in a
webcast from the ADA meeting in New Orleans on 12 June 2016.
The presentation included pictures of typical patients
treated with Endobarrier to show what happened to them, and
also MRI scans demonstrating the considerable reduction in
amount of fat in the liver and pancreas caused by the weight
loss. There was also a discussion of the rare hepatic
abscess complication. |
